



May 18th, 2:30 PM - 3:00 PM

Rewriting the Rules for Diagnostics: Implications of Probability and Measure Theory for SARS-CoV-2 Testing

Paul Patrone

National Institute of Standards and Technology, paul.patrone@nist.gov

Anthony Kearsley

National Institute of Standards and Technology

Follow this and additional works at: <https://scholarscompass.vcu.edu/bamm>



Part of the [Applied Mathematics Commons](#), [Applied Statistics Commons](#), [Biostatistics Commons](#), [Life Sciences Commons](#), [Medicine and Health Sciences Commons](#), and the [Probability Commons](#)

<https://scholarscompass.vcu.edu/bamm/2022/wed/29>

This Event is brought to you for free and open access by the Dept. of Mathematics and Applied Mathematics at VCU Scholars Compass. It has been accepted for inclusion in Biology and Medicine Through Mathematics Conference by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.

Rewriting the Rules for Diagnostics: Implications of Probability and Measure Theory for SARS-CoV-2 Testing

Paul Patrone, Anthony Kearsley

Estimating prevalence, i.e. the fraction of a population that has been previously infected by a disease such as SARS-CoV-2, is among the most important tasks in epidemiology. When estimating prevalence, it is often assumed that diagnostic classification of samples is necessary. However, this assumption is false. In this talk, I demonstrate that a perspective rooted in metrology is necessary to formulate the mathematical framework describing a diagnostic test. In particular, I show how conditional probability models of diagnostic measurement outcomes for positive and negative samples yield: (i) an unbiased and converging estimate of prevalence without classifying samples; and (ii) an minimum-error classification strategy. I will show how traditional prevalence estimates fail to converge and that a minimum uncertainty prevalence estimation strategy can be constructed in terms of the *bathtub principle*. Throughout the talk, I will use examples from real-world SARS-CoV-2 antibody tests to illustrate main ideas and validate the analysis.